Sign up
Pharma Capital

Futura Medical phase III trial on track to begin in September; out-licensing agreement "remains a top priority"

The company's flagship product is a fast-acting gel for erectile dysfunction
The company's condom range received regulatory sign-off in Kuwait recently

The phase III clinical trial of Futura Medical PLC's (LONFUM) fast-onset gel for erectile dysfunction is on track for first patient dosing in September, chairman John Clarke confirmed ahead of the company's annual meeting later.

He added that the completion of a significant out-licensing agreement for MED2002 "remains a top priority" as he investors were told: "Whilst negotiations proceed, we will continue to maintain the momentum in the product's development.

READ: Futura Medical starts work on Phase III trial for its erectile dysfunction gel

In an update on progress, Clarke said preparations for the launch of its CSD500 condom in new territories were underway after it received regulatory sign-off in Kuwait and with the product now on sale in Saudi Arabia. 

On TPR100, Futura's diclofenac gel for pain relief, the chairman said the company was waiting for the manufacturer Thornton & Ross to submit its UK regulatory dossier to the Medicines & Healthcare products Regulatory Agency.

"Futura has a strong balance sheet, an experienced team, an exciting product portfolio and a particularly valuable asset in MED2002, which has the potential to be the world's fastest-acting erectile dysfunction treatment," said Clarke.  

"We look forward to providing further updates in the current financial year."


Why Invest In Futura Medical PLC? Read More Here

Register here to be notified of future FUM Company articles
View full FUM profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.